To evaluate the effect of recombined human growth hormone therapy on the GH resistance state of liver cirrhosis with different Child-Pugh score and on their low serum albumen state. 51 patients were divided into two groups, including Child-pugh 5-8, 25 cases and Child-Pugh 9-15, 26 cases. Cases were further divided into treatment group (treated with rGH) and control group (The treated with human blood albumen) according to randonized block design for 10 days. Plasma GH, IGF-1 were measured by RIA before treatment, 24h after treatment and the end of treatment, respectively. GH level in liver cirrhosis is higher than that in health (P<0.05) , but IGF-1 level decrease obviously (P<0.01) . The GH resistance of liver cirrhosis was improved by rGH therapy. At the end of treatment, GH level of liver cirrhosis in Child-Pugh 9-15 is higher than that in Child-Pugh 5-8 (9.91±7.61 vs 4.75±3.94, μg/L, P<0.05) , contrarily, IGF-1 level is less (48.43±16.88 vs 63.47±22.19, μg/L, P<0.05) .Low ALB level in liver cirrhosis were improved by rGH therapy. The GH resistance in liver cirrhosis, especially low Child-Pugh score cirrhosis, and their low albumen state can be improved by rGH therapy.
DownLoad: